What is SynAgile?
SynAgile is a pharmaceutical firm dedicated to developing novel treatments for Parkinson's disease. The company's proprietary OraFuse Technology offers a non-invasive method for oral drug delivery, aiming to improve patient compliance and therapeutic efficacy. This focus on patient-centric innovation positions SynAgile within a critical segment of the healthcare market, addressing unmet needs in neurodegenerative disease management.
How much funding has SynAgile raised?
SynAgile has raised a total of $19.4M across 2 funding rounds:
Private Equity
$10.4M
Debt
$9M
Private Equity (2017): $10.4M with participation from TAMCAP LLC
Debt (2021): $9M, investors not publicly disclosed
Key Investors in SynAgile
TAMCAP LLC
TAMCAP LLC is a firm operating within the Custom Software & IT Services industry, suggesting a potential interest in technology-driven healthcare solutions and operational efficiency.
What's next for SynAgile?
The recent major strategic investment, coupled with the overall enterprise-level funding SynAgile has attracted, indicates strong investor confidence in the company's technology and market potential. This capital infusion is expected to accelerate the development and potential commercialization of its Parkinson's treatments. The company is likely to focus on advancing its clinical trials, expanding its research and development capabilities, and potentially forging strategic partnerships to bring its OraFuse Technology to a wider patient population.
See full SynAgile company page
